Skip to main content

Table 5 Diagnostic performance of dual-energy CT parameters in differentiating lateral metastatic from nonmetastatic lymph nodes in PTC patients with and without HT

From: Effect of Hashimoto’s thyroiditis on the dual-energy CT quantitative parameters and performance in diagnosing metastatic cervical lymph nodes in patients with papillary thyroid cancer

 

Threshold

AUC

Sensitivity

Specificity

HT+/LLN + vs. HT+/LLN-

    

 ICA (mg/mL)

 NICA

 ZeffA

 λHUA

 ICV (mg/mL)

 NICV

 ZeffV

1.550

0.193

8.350

3.398

2.950

0.523

8.950

0.780

0.780

0.780

0.800

0.668

0.649

0.644

0.792

0.792

0.792

0.792

0.417

0.542

0.417

0.638

0.698

0.638

0.711

0.966

0.765

0.946

HT-/LLN + vs. HT-/LLN-

    

 ICA (mg/mL)

 NICA

 ZeffA

 λHUA

 ICV (mg/mL)

 NICV

 ZeffV

 λHUV

2.050

0.226

8.550

4.310

2.250

0.577

8.750

4.601

0.980

0.989

0.978

0.971

0.926

0.952

0.922

0.914

0.914

0.971

0.914

0.914

0.886

0.829

0.829

0.886

0.977

0.969

0.969

0.969

0.855

0.962

0.901

0.878

  1. Note: PTC, papillary thyroid cancer; HT, Hashimoto’s thyroiditis; HT+, PTC with HT; HT-, PTC without HT; LLN+, metastatic lateral lymph nodes; LLN-, nonmetastatic LLNs; ICA/ICv, iodine concentration in arterial/venous phase; NICA/NICV, normalized ICA/ICv; λHUAHUV, slope of the spectral Hounsfield unit curve in arterial/venous phase; ZeffA/ZeffV, effective atomic number in arterial/venous phase. AUC, area under the curve
  2. Threshold ICA/ICv are represented as mg/mL